BioCentury
ARTICLE | Finance

IPO for Rib-X

Cash poor antibiotics play Rib-X files for IPO; Phase IIb data by year end

December 5, 2011 8:00 AM UTC

Antibiotics play Rib-X Pharmaceuticals Inc. hopped into the IPO queue last week with scant cash on hand and a compound in Phase IIb testing.

At Sept. 30, Rib-X had $9.7 million in cash. It reported an operating loss of $29.1 million in the first nine months. It filed to raise up to $80 million in an offering underwritten by Deutsche Bank; William Blair; Lazard; and Needham...